Bio-Thera Solutions, Ltd. (SHA:688177)

China flag China · Delayed Price · Currency is CNY
23.03
-0.42 (-1.79%)
Apr 17, 2026, 4:00 PM EDT
Market Cap9.37B +15.0%
Revenue (ttm)933.69M +25.6%
Net Income-336.44M
EPS-0.81
Shares Out414.08M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,795,710
Average Volume3,533,553
Open23.25
Previous Close23.45
Day's Range22.72 - 23.40
52-Week Range20.15 - 36.32
Beta0.53
RSI48.53
Earnings DateApr 28, 2026

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epitheli... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 1,266
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688177
Full Company Profile

Financial Performance

In 2025, Bio-Thera Solutions's revenue was 933.69 million, an increase of 25.64% compared to the previous year's 743.17 million. Losses were -336.44 million, -34.07% less than in 2024.

Financial Statements